On Tuesday, Syndax Pharmaceuticals Inc SNDX revealed topline results from the relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib.
The cohort met the primary endpoint with a complete remission (CR) plus CR with a partial hematological recovery (CRh) rate of 23% among the efficacy evaluable adults.
Among the patients who achieved CR/CRh, 12 had a CR, and three had a CRh.
At the data cutoff, the observed median duration of CR/CRh responses was 4.7 months, with three patients remaining in response.
Minimal residual disease (MRD) status was assessed in 14 of 15 patients who achieved CR/CRh, 64% (9/14) of whom were MRD negative. The overall response rate (ORR) was 47%.
17% of patients who achieved an overall response underwent hematopoietic stem cell transplant (HSCT) following treatment with revumenib, with three resuming revumenib therapy post-transplant.
The safety population included 84 adult and pediatric patients with R/R mNPM1 AML in the Phase 2 portion of the AUGMENT-101 trial.
The safety profile observed with revumenib in this population was consistent with previously reported data.
Treatment-related adverse events (TRAEs) leading to treatment discontinuations were 5%
The company is conducting several trials of revumenib across the treatment landscape in mNPM1 and KMT2A-rearranged (KMT2Ar) acute leukemias.
Syndax expects to achieve the following upcoming revumenib milestones:
- Receive FDA approval for R/R KMT2Ar acute leukemias in the fourth quarter of 2024.
- Initiate a pivotal combination trial with venetoclax/azacitidine in newly diagnosed mNPM1 AML or KMT2Ar acute leukemias by year-end 2024.
- Publish pivotal AUGMENT-101 results in R/R mNPM1 AML patients and present results at a medical conference in the first half of 2025.
- Submit a supplemental NDA for R/R mNPM1 AML in the first half of 2025.
Price Action: SNDX stock is down 22.1% at $16.96 at last check Tuesday.
Read Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.